Subjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug efficacy, safety and tolerability.

Inclusion Criteria:

• Males or females between the ages of 18 and 60 with mild to moderate asthma